We report a case of a young female who presented with dyspnea on exertion and was found to have pulmonary hypertension related to HIV infection. A brief review of current literature on pulmonary hypertension associated with HIV infection follows. HIVassociated pulmonary hypertension (PHT) is a well-recognized condition, with an estimated incidence of 1 in 200 HIV cases. Progressive shortness of breath is the most common presentation. Doppler echo study is a widely accepted as a tool to determine the pulmonary artery systolic pressure and lung biopsy is usually performed after workup for secondary pulmonary hypertension. There is no pathognomonic histopathological feature, though plexogenic pulmonary arteropathy is type most commonly seen. There seems to be no correlation between CD4 cell counts or history of opportunistic infection and the development or progression of pulmonary hypertension. HIV associated pulmonary hypertension is a diagnosis of exclusion. HIV patients present at a younger age, at an earlier stage with lower mean pulmonary artery pressure, and most importantly, run more aggressive course. Treatments with oral anticoagulation and calcium channel blockers have been disappointing. Some data showed that epoprostenol is promising. But its use is generally limited to seriously ill patients and a larger study with a long-term follow up is needed.
CASE REPORT
A 44 year old female with no significant past medical history, presented with progressive shortness of breath on exertion for 1 month. The shortness of breath was associated with dry cough and palpitation. The patient experienced decrease in functional class over a month. She used to walk eight blocks before, but now can only walk half a block limited by shortness of breath. She also had a three-pillow orthopnea, but did not recall any pressure-type chest pain on exertion, calf pain, rash or fever. Her internist for an asthma attack treated her without improvement in her symptoms. She denied any other medical problems in the past or to taking any elicit drugs but did report having smoked a few cigarettes a day for the past 20 years until a month ago. She had no significant family history.
On physical examination, she was a well-built, wellnourished young female with normal blood pressure of 100/60, heart rate of 106 beats per minute and mild dyspnea at rest with a respiratory rate of 18/min. She was alert and oriented. No jugular venous distension or carotid bruit was noted. The cardiovascular examination revealed normal apex beat, normal heart sounds, and tachycardia with gallop heart sound. Lungs were clear to percussion and auscultation.
Abdominal examination was unremarkable. Extremities showed symmetrical pulse and no pedal edema.
The ECG showed sinus rhythm with T wave inversion in leads III and V1-V3. The T wave inversion in leads V1-V3 was new compared to a prior ECG done two months ago. The patient was referred to the cardiologist for a nuclear stress test to rule out myocardial ischemia. The patient underwent an exercise stress test with myocardial perfusion imaging using Tc-99m Sestamibi. The stress ECG and myocardial perfusion imaging were normal with a severely enlarged right ventricle (see Figure 1 ). The patient was admitted to rule out pulmonary embolism.
Chest film showed mild cardiomegaly, enlarged pulmonary trunk and branch pulmonary arteries. Arterial blood gas on room air revealed chronic respiratory alkalosis with a high alveolar-arterial gradient. An echocardiogram was done to evaluate the chamber size and function, which revealed right ventricular dilatation with flattening of the septum, D-shaped ventricle and paradoxical septal motion, dilatation of the pulmonary trunk and bifurcation but no obvious thrombus was seen. These were new changes compared to normal echocardiogram ten months earlier. Spiral CT of the chest was done which showed no evidence of pulmonary embolism. A ventilation-perfusion scan was also done which was reported as low probability for pulmonary embolism. A right heart catheterization was done to evaluate the rightsided pressures and it revealed a right atrial pressure of 6 mmHg, right ventricular pressure of 58/6 mmHg, severe pulmonary hypertension with a pressure of 60/30 mmHg and a pulmonary capillary wedge pressure of 7 mmHg. Pulmonary consult was called and a lung biopsy was suggested to rule out pulmonary hypertension due to pulmonary parenchymal diseases. The lung biopsy showed lymphocytic infiltrate suggestive of lymphocytic interstitial pneumonitis. Microbial stains were negative. Patient was also tested for HIV infection, which came back positive with a CD4 cell count of 195. Patient was seen by infectious disease specialists and started on antiretroviral treatment. Subsequent to an effective antiretroviral treatment a significant improvement in pulmonary hypertension as well as right ventricle size was observed.
REVIEW OF LITERATURE
Because of the recent advances in antiretroviral therapy, patients who are infected with the Human Immune Deficiency Virus (HIV) tend to live longer. 1 , 2 Furthermore, non-infectious complications have become a more frequent cause of morbidity and mortality. Cardiac involvement from non-opportunistic infection in AIDS patients was first reported in 1983 in an autopsy case with myocardial Kaposi's Sarcoma. 3 Approximately 28 to 73% of AIDS patients have been reported to have cardiac involvement, 4 with the most common form being pericardial effusion, which has been reported to be as frequent as 20 % (range 10-40%). 5 , 6 , 7 , 8 Pulmonary hypertension in AIDS patients or HIV-associated pulmonary hypertension (PHT), as in our demonstrated case, has been well recognized as a noninfectious complication in these patients.
INCIDENCE
Since first reported by Kim and Factor in 1987 9 , HIVassociated PHT has been increasingly described in the literature. Until October 2000, 131 cases have been reported in the world literature. 10 The accurate incidence of HIVassociated PHT is unknown, but estimated to be 1 in 200 HIV cases, according to a study in 1989 by Hilmelman, et al. 12 Its incidence in the general population averages 1 in 200 000. This incidence should be as high as 7.1-8% among HIV or AIDS patients who presented with cardiopulmonary symptoms and signs. 13 , 14 
PATHOGENESIS
The pathogenesis of HIV associated PHT is not yet determined. The hypothesis of direct effect of HIV on pulmonary vascular endothelium or smooth muscle has not been proved in vivo. Mette, et al. failed to demonstrate HIV in pulmonary vascular endothelium in these patients, who have primary pulmonary hypertension, with electron microscopy, immunohistochemistry, DNA in situ hybridization and PCR techniques. 27 It has become more evident that HIV may indirectly stimulate the vascular endothelium and smooth muscle cell growth, along with vasoconstriction via some mediators and cytokines. In patients with PHT, the increase in serum interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-) concentrations 28 , supported this hypothesis. Furthermore, serum endothelin-1 also increased in these patients. 29 The link to HIV was clearer when the HIV glycoprotein gp 120 was found to stimulate endothelin-1 and TNF-secretion from macrophages in these patients in a concentration-dependent fashion. 30 The other possibility is autoimmune phenomenon, since HIV associated PHT patients have been reported to have significantly higher serum anticardiolipin IgM, anti SS-B and neopterin compared with matched control subjects. 25 At last, genetic predisposition may play a major role in susceptibility to developing PHT in HIV patients, evidenced by only a small proportion of HIV patients developing this problem. Morse, et al. found the significant increase frequency of HLA-DR6 and of HLA-DR52 in the HIV patients with PHT compared with non-HIV matched subjects and HIV matched subjects who do not have PHT.
CLINICAL FEATURES
The largest collective review to date 10 showed that progressive shortness of breath is the most common presentation, along with pedal edema, non-productive cough, fatigue, syncope or near-syncope and chest pain. Physical findings include the common signs of pulmonary hypertension, i.e. jugular venous distension, a loud P2, rightsided S3 gallop, tricuspid and pulmonary regurgitation murmur and peripheral edema. (Table I ) There seems to be no correlation between CD4 cell counts (range from 0 to 937 cells/mm 3 , mean 269) or history of opportunistic infection and the development or progression of HIV associated pulmonary hypertension. 10 But Pellicelli and colleagues did report a statistically significant difference between HIV positive patients with AIDS and those without AIDS with regard to degree of pulmonary hypertension, with AIDS patients having a higher pulmonary artery systolic pressure. 
DIAGNOSIS
As in idiopathic primary pulmonary hypertension, HIV associated pulmonary hypertension is a diagnosis of exclusion. Secondary causes of pulmonary hypertension, i.e. chronic hypoxemia, chronic pulmonary diseases, pulmonary thromboembolism, portal hypertension and talc granuloma (especially in IV drug abusers) must be sought and excluded. Provisional diagnosis is usually made by an echocardiogram. Doppler echo study is widely accepted as a tool to determine the pulmonary artery systolic pressure. 15 Right heart catheterization usually confirms the diagnosis, and reveals elevated right-sided filling pressure and high pulmonary artery pressure with essentially normal pulmonary capillary wedge pressure. Mehta et al reported that the average pulmonary artery pressure in HIV associated PHT was (mean ± SD) 67 ± 18 / 40 ± 11 mmHg, with systolic pulmonary pressure range from 33 to 120 mmHg and diastolic pressure ranging from 21 to 70 mmHg. 10 Lung biopsy is usually performed after workup for secondary pulmonary hypertension, i.e. arterial blood gas, pulmonary function testing and ventilation-perfusion scan, reveals no positive cause. Pulmonary histopathology 10 demonstrated plexogenic pulmonary arteriopathy in 78% of the patients, medial hypertrophy and intimal fibrosis without plexiform lesion 11%, pulmonary veno-occlusive disease 7%, and thrombotic pulmonary arteriopathy 4%. Although plexogenic pulmonary arteropathy is the most common histopathological feature in HIV associated PHT, it is not pathognomonic. There are some other medical conditions i.e. portal hypertension, chronic hepatitis with liver cirrhosis, connective tissue diseases, and some type of congenital heart diseases, reported to have pulmonary arteriopathy type pulmonary hypertension. 16 , 17 , 18 , 19 
TREATMENT
To date, there is no known certain therapeutic approach to the patients with HIV associated PHT. Most patients receive supportive treatment for right-sided heart failure and pulmonary hypertension, such as oxygen supplement and diuretics. Oral anticoagulation have shown to significantly improve survival in patients with non-HIV related primary PHT 15 ,20 but results in HIV associated PHT has not been conclusive enough to encourage the use in this group of patients. 12 , 21 , 22 , 23 Treatment with oral calcium channel blockers, which have shown to improve survival in subgroups of non-HIV related primary PHT patients, have discouraging data in HIV associated PHT. 24 , 25 Only Epoprostenol, an intravenous prostacycline, has been reported to improve hemodynamic and functional status acutely 24 , 26 and in the long run (12-40 months). 26 Also, there is no difference in response to epoprostenol therapy between HIV associated PHT compared with primary pulmonary hypertension patients. 24 Epoprostenol therapy is generally limited to seriously ill patients 26 because of its cost and the need for continuous intravenous infusion. The role of antiretroviral agents in HIV associated PHT have been disappointing. Some data showed to decrease right heart pressure with antiretroviral medications 25 but some study showed no clinical benefit, but rapid deterioration of clinical course in some patients. 14 
CLINICAL COURSE
Compared with primary pulmonary hypertension, the patients with HIV associated PHT present at a younger age, at a lower mean pulmonary artery pressure and at the lesser degree of disability, classified by NYHA. 24 Nevertheless, PHT in HIV patients run a more aggressive course, shown by having the same survival rate at two year follow up (46% and 53%). 24 In the same study, most of the HIV patients (80%) died from pulmonary hypertension at one year. 24 A second study of HIV associated PHT reported a survival rate of 58% at one year with a median survival of 1.3 years, compared to 2.6 years in matched controls HIV patients without PHT (P<0.05). 25 In other words, the presence of pulmonary hypertension in HIV patients reduces the probability of survival by 50%.
CONCLUSION
HIV associated PHT has been a well recognized condition. The association between these two conditions is more than a coincidence, since the incidence of pulmonary hypertension in HIV patients is 1000 times higher than in the general population. The presentation, hemodynamic profile, the lung histo-pathology and the response to epoprotenol, are not different from primary pulmonary hypertension, except that HIV patients present at a younger age, at an earlier stage with lower mean pulmonary artery pressure, and most importantly, run more aggressive course. Treatments with oral anticoagulation and calcium channel blockers have been disappointing. Although some data showed that epoprostenol is promising, a larger study population and a better-designed study with a long term follow up is needed before a standard recommendation can be made. 
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